List of Excipients in Branded Drug SIMBRINZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	SIMBRINZA	brinzolamide/brimonidine tartrate	0065-4147	BENZALKONIUM CHLORIDE	2030-10-30
Alcon Laboratories Inc	SIMBRINZA	brinzolamide/brimonidine tartrate	0065-4147	BORIC ACID	2030-10-30
Alcon Laboratories Inc	SIMBRINZA	brinzolamide/brimonidine tartrate	0065-4147	CARBOMER HOMOPOLYMER TYPE B	2030-10-30
Alcon Laboratories Inc	SIMBRINZA	brinzolamide/brimonidine tartrate	0065-4147	HYDROCHLORIC ACID	2030-10-30
Alcon Laboratories Inc	SIMBRINZA	brinzolamide/brimonidine tartrate	0065-4147	MANNITOL	2030-10-30

SIMBRINZA Excipient Strategy and Commercial Opportunities

Last updated: November 3, 2026

Simbrinza is a fixed-dose ophthalmic suspension containing brinzolamide 1% and brimonidine tartrate 0.2% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its commercial differentiation depends heavily on suspension performance, preservative management, ocular tolerability, and packaging rather than on the active ingredients alone. The strongest opportunities are preservative-free delivery, improved redispersibility, lower ocular-surface burden, and device-enabled differentiation. [1]

What is Simbrinza and how do its excipients support the product?

Simbrinza combines two intraocular-pressure-lowering mechanisms in one multidose ophthalmic suspension:

Component	Concentration or role
Brinzolamide	1.0%, carbonic anhydrase inhibitor
Brimonidine tartrate	Equivalent to brimonidine 0.2%, alpha-2 adrenergic agonist
Benzalkonium chloride	0.01%, antimicrobial preservative
Carbomer 974P	Suspending and viscosity-enhancing polymer
Boric acid	Buffering and tonicity support
Mannitol	Tonicity adjustment and formulation stabilization
Sodium chloride	Tonicity adjustment
Tyloxapol	Wetting and dispersion aid
Purified water	Vehicle
Hydrochloric acid and/or sodium hydroxide	pH adjustment

The formulation is an aqueous suspension rather than a true solution. Brinzolamide has limited aqueous solubility, which requires particle dispersion. Carbomer 974P contributes viscosity and helps maintain a uniform suspension. Tyloxapol improves wetting of hydrophobic or poorly water-soluble particles and assists redispersion after storage. [1,2]

The excipient system must balance four competing requirements:

1. Maintain uniform drug concentration throughout the bottle.
2. Permit rapid and complete redispersion after shaking.
3. Avoid excessive viscosity that impairs drop formation or causes blurred vision.
4. Preserve the product against microbial contamination during repeated use.

The label instructs patients to shake the bottle well before use. That instruction is a commercial signal that suspension uniformity is central to product performance. [1]

What excipient strategy does Simbrinza use?

Simbrinza uses a conventional multidose ophthalmic suspension strategy built around polymer-assisted suspension, wetting, buffering, isotonicity control, and benzalkonium chloride preservation.

Suspension and redispersibility

Carbomer 974P is the primary rheology modifier. In this application, the polymer can increase residence time on the ocular surface and reduce sedimentation. Excessive polymer concentration, however, could increase dispensing force, produce stringiness, and cause transient visual disturbance.

Tyloxapol supports particle wetting and reduces the risk of hard sediment formation. For a generic or lifecycle-management product, the relevant performance targets include:

• Sedimentation rate
• Ease of redispersion
• Number of inversions required for uniformity
• Particle-size distribution
• Delivered-dose uniformity
• Viscosity across shear rates
• Drop size and bottle-drug interaction

These attributes are more commercially important than simply matching the inactive-ingredient list.

pH and ocular comfort

The product label specifies a pH range of approximately 6.5 to 8.0. [1] The pH must support chemical stability and suspension performance while limiting burning and stinging. Brinzolamide and brimonidine have different ionization and solubility characteristics, making pH optimization more complex than in a single-active ophthalmic product.

A reformulator cannot assume that a higher or lower pH will improve performance. Any pH change can affect:

• Brinzolamide dissolution and precipitation
• Brimonidine chemical stability
• Polymer hydration
• Preservative effectiveness
• Ocular tolerability
• Container compatibility

Tonicity management

Boric acid, mannitol, and sodium chloride collectively contribute to osmolality and formulation robustness. The combination allows the sponsor to manage tonicity without relying on a single excipient at a concentration that could compromise comfort or stability.

A commercial follow-on product could explore a lower-excipient-load formulation, but the resulting product would need to demonstrate comparable comfort, stability, dose uniformity, and antimicrobial protection.

Preservative strategy

Simbrinza uses benzalkonium chloride, commonly called BAK, at 0.01%. BAK is effective against a broad range of microorganisms and is widely used in multidose ophthalmic products. Its commercial disadvantage is cumulative ocular-surface exposure, particularly in patients using multiple chronic glaucoma medications.

The BAK concentration creates two competing commercial positions:

• It supports a conventional multidose bottle with a familiar manufacturing and regulatory profile.
• It creates an opening for preservative-free or low-preservative competitors targeting ocular-surface disease, contact-lens users, and adherence-sensitive patients.

The presence of BAK does not by itself establish that a preservative-free product would be clinically superior. The opportunity depends on demonstrating meaningful tolerability or adherence benefits without sacrificing sterility and shelf life.

What formulations are protected by the Simbrinza excipient system?

The commercial value of the Simbrinza formulation lies in the integrated product architecture rather than in any single excipient. Potentially protectable technical features include:

Potential protection area	Commercial relevance
Brinzolamide-brimonidine fixed-dose suspension	Supports combination-product differentiation
Particle-size distribution	Controls dose uniformity and settling
Polymer and surfactant combination	Supports redispersion and physical stability
pH and osmolality window	Balances stability and ocular comfort
Preservative system	Supports multidose sterility
Bottle and dropper design	Controls delivered volume and contamination risk
Suspension manufacturing process	May limit easy replication
Preservative-free container system	Supports lifecycle extension

An excipient list alone is generally weak protection. The stronger technical position is a claimed combination of concentrations, particle properties, rheology, manufacturing conditions, and container performance.

For a generic applicant, formulation development would likely focus on showing pharmaceutical equivalence and comparable performance rather than copying every excipient at the same concentration. FDA guidance for ophthalmic products places importance on sterility, physicochemical characteristics, particulate matter, viscosity, pH, osmolality, and delivered dose. [3]

What commercial opportunities exist for Simbrinza excipients?

Preservative-free Simbrinza

The most visible opportunity is a preservative-free version in unit-dose containers or a multidose bottle using a validated antimicrobial system.

A preservative-free product could target:

• Long-term glaucoma patients with ocular-surface symptoms
• Patients receiving several preserved eye drops
• Patients with preservative intolerance
• Contact-lens users
• Ophthalmology practices seeking ocular-surface-friendly regimens

Unit-dose packaging increases material and manufacturing costs and may reduce convenience. A preservative-free multidose container could offer stronger commercial economics but requires a high-performance closure or valve system that limits microbial ingress during repeated use.

Low-BAK or alternative-preservative products

A reduced-BAK formulation could preserve multidose convenience while lowering cumulative preservative exposure. The main technical barriers are antimicrobial effectiveness, preservative adsorption to packaging, extractables and leachables, and chemical compatibility with the suspension.

Alternative systems may include oxidative preservatives or preservative-free mechanical designs. Each approach can alter ocular comfort, container cost, regulatory testing, and supply-chain complexity.

Improved suspension performance

A product with faster redispersion and less settling could reduce dosing variability. Commercial claims could focus on ease of use, but claims must be supported by objective product-performance data.

Potential formulation routes include:

• Optimized carbomer concentration
• Alternative cellulose or synthetic polymer systems
• Modified particle-size distribution
• Improved wetting-agent selection
• Controlled flocculation
• Lower-viscosity high-uniformity suspensions

A lower-viscosity product may produce a more acceptable drop and less temporary blurring. A higher-viscosity product may improve retention but create dispensing and comfort problems.

Device-enabled differentiation

The bottle and closure system offer a separate commercial pathway. Possible improvements include:

• One-handed dispensing
• Controlled drop size
• Inversion or shaking assistance
• Dose counters
• Low-residual-volume bottles
• Microbial ingress protection
• Unit-dose or multidose preservative-free formats

For a combination suspension, a device that improves shaking compliance could have more practical value than a minor excipient change. The principal development risk is regulatory classification and the need to demonstrate consistent delivered dose throughout shelf life.

How does Simbrinza compare with competing glaucoma products?

Simbrinza competes with both fixed-dose and separate-component regimens.

Product category	Typical advantage	Excipient or commercial weakness
Simbrinza	Combines carbonic anhydrase inhibition and alpha-2 agonism in one bottle	BAK exposure; suspension must be shaken
Brinzolamide monotherapy	Single active ingredient; established formulation	Requires combination with another bottle when additional pressure reduction is needed
Brimonidine monotherapy	Established alpha-2 agonist option	Does not provide carbonic anhydrase inhibition
Brimonidine-timolol combinations	Strong fixed-dose convenience	Timolol contraindications and systemic beta-blocker concerns
Dorzolamide-timolol combinations	Established combination category	Different tolerability and dosing considerations
Prostaglandin analogs	Often once-daily dosing	Ocular-surface and cosmetic adverse effects; mechanism differs
Preservative-free glaucoma products	Ocular-surface positioning	Higher packaging and manufacturing cost

The key competitive advantage of Simbrinza is the combination of two non-beta-blocker mechanisms in one product. Its principal formulation disadvantage is the combination of suspension handling and BAK exposure.

What FDA regulatory issues affect a Simbrinza follow-on product?

A follow-on product would generally need to address the regulatory requirements applicable to an ophthalmic suspension and a fixed-dose combination. Relevant FDA considerations include:

• Sterility assurance
• Container-closure integrity
• Particulate matter
• Appearance and resuspendability
• Particle-size distribution
• pH and osmolality
• Viscosity and rheological profile
• Delivered volume
• Dose uniformity
• Preservative effectiveness
• Stability under long-term and accelerated conditions
• Extractables and leachables
• Drug-device compatibility

An ANDA applicant would face a higher technical burden than an ophthalmic solution applicant because suspension performance can materially influence delivered dose. The applicant would also need to manage differences in inactive ingredients, packaging, and manufacturing process.

The most defensible development strategy is to establish a quality target product profile before selecting a substitute excipient system. The target should include redispersion time, sedimentation behavior, dose uniformity, drop size, ocular comfort, and microbial protection.

When does Simbrinza lose exclusivity and what is the generic-entry risk?

Simbrinza received FDA approval in 2013. Its active ingredients, brinzolamide and brimonidine, were previously established products. The relevant commercial protection therefore depends primarily on product-specific formulation, combination, method-of-use, and regulatory exclusivity rights rather than on new chemical entity exclusivity. [1,4]

The practical generic-entry risk has several layers:

Risk layer	Assessment
Active-ingredient patents	Limited strategic barrier because both actives predate Simbrinza
Fixed-dose combination patents	Potentially relevant if claims cover composition or use
Formulation patents	Relevant where particle size, polymer system, pH, or stability is claimed
Method-of-use patents	Relevant only if listed and enforceable for the proposed indication
Regulatory exclusivity	Depends on the approval pathway and current FDA records
Manufacturing know-how	May delay entry even where patent protection is limited
Device protection	Could complicate substitution but is less likely to block all formulations

The FDA Orange Book remains the controlling source for current listed patents, expiration dates, pediatric exclusivity, and Paragraph IV certifications. Patent status should be assessed against the live Orange Book record and the relevant court docket before an investment or launch decision. [4]

Which companies are positioned to challenge Simbrinza?

Potential challengers include established ophthalmic generic manufacturers with suspension capabilities, specialized sterile ophthalmic companies, and manufacturers with preservative-free packaging platforms. The strongest candidates are companies that already produce:

• Brinzolamide ophthalmic suspension
• Brimonidine ophthalmic solution
• Fixed-dose glaucoma combinations
• Preservative-free multidose ophthalmic products
• Sterile suspensions in multidose containers

A company with only solution manufacturing capability would face a greater technical barrier. Simbrinza is not readily replicated by blending two existing solutions because brinzolamide requires suspension management and the combined product must remain stable and uniform.

What licensing and partnership opportunities exist?

Commercial opportunities extend beyond a direct generic launch.

Excipient and formulation licensing

Specialty excipient suppliers could license:

• Low-BAK suspension systems
• Preservative-free multidose technology
• High-efficiency wetting systems
• Redispersion-enhancing polymers
• Ophthalmic packaging and valve systems

The most valuable licenses would combine formulation know-how with regulatory precedent and scalable sterile manufacturing.

Contract development and manufacturing

CDMOs with ophthalmic suspension capabilities can support:

• ANDA formulation development
• 505(b)(2) reformulation programs
• Preservative-free lifecycle products
• Regional licensing products
• Dual-source supply strategies

Lifecycle-management products

The original sponsor or a licensee could pursue:

• Preservative-free Simbrinza
• Lower-BAK Simbrinza
• Unit-dose Simbrinza
• A smaller-volume or improved-dose bottle
• A formulation with improved redispersion
• Regional presentations adapted to local preservative preferences

A reformulated product would need a clear commercial benefit because clinicians can already prescribe the components separately or use other fixed-dose glaucoma combinations.

What is the revenue exposure and market opportunity?

Simbrinza revenue is exposed to three commercial pressures:

1. Generic fixed-dose combination entry.
2. Preservative concerns in chronic glaucoma therapy.
3. Substitution by other combination products or separate-component regimens.

No reliable standalone revenue conclusion should be drawn from the broader Alcon ophthalmic portfolio because public reporting generally aggregates products by business segment rather than disclosing Simbrinza-specific sales. [5]

The addressable opportunity is strongest in chronic-use patients who need more than one mechanism but have ocular-surface intolerance or poor adherence with multiple bottles. A preservative-free product could command a premium if it produces measurable tolerability, adherence, or persistence benefits.

Key Takeaways

• Simbrinza is a brinzolamide-brimonidine ophthalmic suspension with BAK preservation.
• Carbomer 974P and tyloxapol are central to suspension stability, wetting, and redispersion.
• The main commercial weakness is cumulative BAK exposure in chronic glaucoma treatment.
• The strongest lifecycle opportunities are preservative-free delivery, low-BAK formulations, improved redispersion, and advanced multidose packaging.
• Generic development is technically more difficult than copying a solution because suspension uniformity and delivered-dose consistency must be demonstrated.
• Formulation and device claims are more commercially relevant than the individual excipients.
• Current patent, Orange Book, litigation, and Paragraph IV conclusions require review of the live FDA and court records before launch planning.

FAQs

Can Simbrinza be reformulated without benzalkonium chloride?

Yes. A preservative-free Simbrinza could use unit-dose packaging or a validated multidose container-closure system. The primary challenges are sterility assurance, microbial ingress, stability, and cost.

Why does Simbrinza require shaking before use?

Simbrinza contains brinzolamide as a suspension. Shaking redistributes suspended particles and helps maintain dose uniformity during administration.

Is carbomer 974P the main commercial excipient in Simbrinza?

Carbomer 974P is a key suspension and viscosity modifier, but its performance depends on the combined use of tyloxapol, pH adjusters, tonicity agents, and the bottle system.

Would a Simbrinza solution have a commercial advantage?

A true solution could eliminate settling and shaking requirements, but brinzolamide solubility, chemical stability, ocular comfort, and pH constraints make a solution technically difficult.

What is the most attractive Simbrinza lifecycle product?

A preservative-free or substantially reduced-BAK multidose suspension with reliable redispersion and controlled drop delivery offers the clearest combination of clinical positioning and commercial differentiation.

References

1. U.S. Food and Drug Administration. (2023). Simbrinza (brinzolamide and brimonidine tartrate ophthalmic suspension) prescribing information.
2. DailyMed. (n.d.). SIMBRINZA- brinzolamide and brimonidine tartrate suspension. National Library of Medicine.
3. U.S. Food and Drug Administration. (2013). Guidance for industry: Ophthalmic drug products: Quality considerations.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. Alcon Inc. (2024). Annual report and Form 10-K.